SCREENING SYSTEM FOR ANTIAPOPTOSIS THERAPEUTICS

目的是为化合物的筛选提供一种分析方法。 那 防止细胞凋亡。开发的产品和方法 会是 由制药公司用于筛选其 化合物 确定用于治疗帕金森氏症的药物和 其他 神经退行性疾病。同二聚体和异二聚体的形成 在两者之间 Bc1-2蛋白家族的成员促进或阻止细胞 死亡。 其具体目的是产生一种无毒的化验方法 中断 对Bc1-2家族成员之间的二聚体形成进行了定量 用人 重组蛋白之间相互作用的创新应用。 毒品 嵌段二聚体形成是调制的良好候选者 细胞凋亡。第一阶段的目标是开发使用Bax的分析方法 并确定形成同源二聚体的最佳条件 化验 在对候选人进行试点测试之前的受控条件下 毒品。 在第二阶段，该检测将适用于高通量的 机器人 自动筛查系统和系统将扩大到 包括 其他Bc1-2家族成员。

The objective is to provide an assay for the screening of compounds that prevent apoptotic cell death. The product and method developed would be used by pharmaceutical companies for use in screening of their compounds to identify drugs for use in treatments for Parkinson's disease and other neurodegenerative disorders. Homodimer and heterodimer formation between members of the Bc1-2 family of proteins promote or prevent cell death. The specific aim is to produce a non-toxic assay in which disruption of dimer formation between the Bc1-2 family members is quantitated employing the innovative use of interactions between recombinant proteins. Drugs that block dimer formation are good candidates for modulation of apoptosis. The goal of Phase I is to develop the assay using Bax homodimer formation and to determine the optimal conditions for the assay under controlled conditions prior to a pilot testing of candidate drugs. During Phase II, the assay will be adapted for high throughput in robotic automatic screening systems and the system will be expanded to include the other Bc1-2 family members.